Blocking NS3-NS4B Interaction Inhibits Dengue Virus in Non-human Primates

Dengue is a major health threat and the number of symptomatic infections caused by the four dengue serotypes is estimated to be 96 million with annually around 10,000 deaths. However, no antiviral drugs are available for the treatment or prophylaxis of dengue. We recently described the interaction between non-structural proteins NS3 and NS4B as a promising target for the development of pan-serotype dengue virus (DENV) inhibitors. Here we present JNJ-1802-a highly potent DENV inhibitor that blocks the NS3-NS4B interaction within the viral replication complex. JNJ-1802 exerts picomolar to low nanomolar in vitro antiviral activity, a high barrier to resistance and potent in vivo efficacy in mice against infection with any of the four DENV serotypes. Finally, we demonstrate that the small-molecule inhibitor JNJ-1802 is highly effective against viral infection with DENV-1 or DENV-2 in non-human primates. JNJ-1802 has successfully completed a phase I first-in-human clinical study in healthy volunteers and was found to be safe and well tolerated. These findings support the further clinical development of JNJ-1802, a first-in-class antiviral agent against dengue, which is now progressing in clinical studies for the prevention and treatment of dengue.

Citing Articles

Identification and evaluation of bioactive compounds from as potential inhibitors of DENV-2 capsid protein: An integrative study utilizing network pharmacology, molecular docking, molecular dynamics simulations, and machine learning techniques.

Khan M, Zilani M, Hasan M, Hasan N Heliyon. 2025; 11(4):e42594.

PMID: 40051864 PMC: 11883367. DOI: 10.1016/j.heliyon.2025.e42594.

Functional Roles and Host Interactions of Non-Structural Proteins During Replication.

Donaldson M, Zanders L, Jose J Pathogens. 2025; 14(2).

PMID: 40005559 PMC: 11858440. DOI: 10.3390/pathogens14020184.

Druggable genome screens identify SPP as an antiviral host target for multiple flaviviruses.

Qiao W, Xie X, Shi P, Ooi Y, Carette J Proc Natl Acad Sci U S A. 2025; 122(8):e2421573122.

PMID: 39969998 PMC: 11874179. DOI: 10.1073/pnas.2421573122.

A Comprehensive Review of the Development and Therapeutic Use of Antivirals in Flavivirus Infection.

Tripathi A, Chauhan S, Khasa R Viruses. 2025; 17(1).

PMID: 39861863 PMC: 11769230. DOI: 10.3390/v17010074.

Animal Models, Therapeutics, and Vaccine Approaches to Emerging and Re-Emerging Flaviviruses.

Baric T, Reneer Z Viruses. 2025; 17(1).

PMID: 39861790 PMC: 11769264. DOI: 10.3390/v17010001.

References

Bhatt S, Gething P, Brady O, Messina J, Farlow A, Moyes C . The global distribution and burden of dengue. Nature. 2013; 496(7446):504-7. PMC: 3651993. DOI: 10.1038/nature12060. View

Stanaway J, Shepard D, Undurraga E, Halasa Y, Coffeng L, Brady O . The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016; 16(6):712-723. PMC: 5012511. DOI: 10.1016/S1473-3099(16)00026-8. View

Kaptein S, Goethals O, Kiemel D, Marchand A, Kesteleyn B, Bonfanti J . A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. Nature. 2021; 598(7881):504-509. DOI: 10.1038/s41586-021-03990-6. View

Zeng W, Halasa-Rappel Y, Durand L, Coudeville L, Shepard D . Impact of a Nonfatal Dengue Episode on Disability-Adjusted Life Years: A Systematic Analysis. Am J Trop Med Hyg. 2018; 99(6):1458-1465. PMC: 6283510. DOI: 10.4269/ajtmh.18-0309. View

Ebi K, Nealon J . Dengue in a changing climate. Environ Res. 2016; 151:115-123. DOI: 10.1016/j.envres.2016.07.026. View

Gubler D . Dengue, Urbanization and Globalization: The Unholy Trinity of the 21(st) Century. Trop Med Health. 2012; 39(4 Suppl):3-11. PMC: 3317603. DOI: 10.2149/tmh.2011-S05. View

Messina J, Brady O, Golding N, Kraemer M, Wint G, Ray S . The current and future global distribution and population at risk of dengue. Nat Microbiol. 2019; 4(9):1508-1515. PMC: 6784886. DOI: 10.1038/s41564-019-0476-8. View

Ong A, Sandar M, Chen M, Sin L . Fatal dengue hemorrhagic fever in adults during a dengue epidemic in Singapore. Int J Infect Dis. 2006; 11(3):263-7. DOI: 10.1016/j.ijid.2006.02.012. View

Halstead S . Dengue. Lancet. 2007; 370(9599):1644-52. DOI: 10.1016/S0140-6736(07)61687-0. View

10.

Katzelnick L, Gresh L, Halloran M, Mercado J, Kuan G, Gordon A . Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017; 358(6365):929-932. PMC: 5858873. DOI: 10.1126/science.aan6836. View

11.

Thomas S, Yoon I . A review of Dengvaxia®: development to deployment. Hum Vaccin Immunother. 2019; 15(10):2295-2314. PMC: 6816420. DOI: 10.1080/21645515.2019.1658503. View

12.

Wilder-Smith A . The first licensed dengue vaccine: can it be used in travelers?. Curr Opin Infect Dis. 2019; 32(5):394-400. DOI: 10.1097/QCO.0000000000000573. View

13.

Fongwen N, Wilder-Smith A, Gubler D, Ooi E, Salvana E, de Lamballerie X . Target product profile for a dengue pre-vaccination screening test. PLoS Negl Trop Dis. 2021; 15(7):e0009557. PMC: 8320982. DOI: 10.1371/journal.pntd.0009557. View

14.

Low J, Gatsinga R, Vasudevan S, Sampath A . Dengue Antiviral Development: A Continuing Journey. Adv Exp Med Biol. 2018; 1062:319-332. DOI: 10.1007/978-981-10-8727-1_22. View

15.

Whitehorn J, Yacoub S, Anders K, Macareo L, Cassetti M, Nguyen Van V . Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions. PLoS Negl Trop Dis. 2014; 8(8):e3025. PMC: 4148227. DOI: 10.1371/journal.pntd.0003025. View

16.

Kou Z, Quinn M, Chen H, Rodrigo W, Rose R, Schlesinger J . Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol. 2007; 80(1):134-46. DOI: 10.1002/jmv.21051. View

17.

Touret F, Baronti C, Goethals O, van Loock M, de Lamballerie X, Querat G . Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery. Antiviral Res. 2019; 168:109-113. DOI: 10.1016/j.antiviral.2019.05.005. View

18.

Williams K, Zompi S, Beatty P, Harris E . A mouse model for studying dengue virus pathogenesis and immune response. Ann N Y Acad Sci. 2009; 1171 Suppl 1:E12-23. DOI: 10.1111/j.1749-6632.2009.05057.x. View

19.

Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R . Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2002; 47(1):350-9. PMC: 148953. DOI: 10.1128/AAC.47.1.350-359.2003. View

20.

Gatti G, Castelli-Gattinara G, Cruciani M, Bernardi S, De Pascalis C, Pontali E . Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children. Clin Infect Dis. 2003; 36(11):1476-82. DOI: 10.1086/375062. View